Medical &Health

Beximco gets FDA approval for antiarrhythmic drug Flecainide

Beximco Pharmaceuticals Limited has received approval from the Food and Drug Administration (FDA) of United States for selling Flecainide Acetate, an antiarrhythmic drug in US market.


Flecainide Acetate medicine is used for treating irregular heartbeats in conditions such as tachycardia and atrial fibrillation, said a press release.


This is Beximco Pharma’s eighth Abbreviated New Drug Application (ANDA) which has been successfully approved for the US market.


Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, said “This approval is another important step in building and strengthening our presence in the US market.”


Source: United News of Bangladesh